DUAC Drug Patent Profile

Which patents cover Duac, and what generic alternatives are available?

Duac is a drug marketed by Stiefel and is included in one NDA.

The generic ingredient in DUAC is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

Summary for DUAC

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for DUAC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DUAC	Gel	benzoyl peroxide; clindamycin phosphate	1% / 5%	050741	1	2008-12-11

US Patents and Regulatory Information for DUAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stiefel	DUAC	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050741-001	Aug 26, 2002	AB	RX	Yes	No

International Patents for DUAC

See the table below for patents covering DUAC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2142530	COMPOSITIONS TOPIQUES CONTENANT DU PEROXYDE DE BENZOYLE ET DE LA CLINDAMYCINE, ET METHODE D'UTILISATION (TOPICAL COMPOSITIONS CONTAINING BENZOYL PEROXIDE AND CLINDAMYCIN AND METHOD OF USE THEREOF)

Supplementary Protection Certificates for DUAC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0591275	SPC/GB05/030	United Kingdom		PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
0137963	97C0042	Belgium		PRODUCT NAME: 2-(2-BENZOYL-SUBSTITUE)-1,3-CYCLOHEXANE-DIONES; REGISTRATION NO/DATE: 8452/B 19930121
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
0186118	SPC/GB05/029	United Kingdom		PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218

Investment Scenario and Fundamentals Analysis for DUAC

Last updated: February 20, 2026

What Is DUAC?

DUAC is a topical combination therapy comprising clindamycin phosphate and benzoyl peroxide. It is primarily approved for the treatment of acne vulgaris. The product is marketed by Sol-Gel Technologies and Medizma, with the generic version available in some markets. DUAC has received FDA approval and is sold in the United States, with its primary competition being other topical acne treatments.

Market Overview

The global acne medication market was valued at approximately $4.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.7% through 2028[1]. Acne treatments accounted for about 40% of topical dermatology drug sales, with significant growth driven by increased urbanization, dermatology awareness, and consumer demand for over-the-counter (OTC) options.

Product Position and Competitive Landscape

DUAC targets moderate to severe acne cases. Its combination of clindamycin and benzoyl peroxide provides antimicrobial and keratolytic effects, reducing bacterial resistance. Its main marketed competitors include:

• Aczone (dapsone gel) by Allergan
• Epiduo (adapalene and benzoyl peroxide) by Janssen
• TactuPulse (clindamycin topical gel), a generic version

Market share for DUAC remains limited due to patent exclusivity until 2024 in the U.S., and competition from OTC options and generics. However, it benefits from established efficacy and dermatologist familiarity.

Regulatory and Patent Landscape

• FDA approval date: October 2012
• Patent expiry: Post-2024, with some formulations potentially facing generic competition earlier due to patent challenges[2].
• Orphan and exclusivity rights: No orphan drug status; patent protections influence pricing power.

Revenue Dynamics

The U.S. market accounts for approximately 70% of DUAC sales, with international markets contributing the remaining 30%. Estimated U.S. sales for 2022 stand around $45 million, with projections favoring growth at a CAGR of 4% up to 2026 (assuming patent exclusivity persists)[3].

Investment Risks and Opportunities

Risks:

• Patent expiration: Opens room for generics erosion. Timing critical.
• Market saturation: Increasing competition from OTC benzoyl peroxide products.
• Pricing pressures: Managed care and payor policies favor generics and lower-cost therapies.
• Regulatory changes: Potential for new labeling restrictions or off-label use bans.

Opportunities:

• Generic entry: May lead to market share loss but also presents opportunities for licensing or acquisition.
• Expansion into new markets: Asia-Pacific and Latin America exhibit rising acne prevalence.
• Line extension: Adjunct formulations, combination with other active ingredients.

Financial Outlook

Given current sales figures and patent landscape, DUAC's revenue is expected to plateau post-2024 barring new formulation approvals or market expansion strategies. Volatility depends heavily on patent litigation outcomes and regulatory developments. The drug's EBITDA margins are estimated at 35-40%, with potential downside from patent expiries and increased generic competition. Investment thesis hinges on the timing of patent cliff and market penetration in emerging economies.

Key Investment Considerations

Factor	Impact	Status
Patent expiry	High risk for revenue erosion	Post-2024
Market growth	Supports long-term revenue	Moderate, 4-5% CAGR
Competition	Intensifies from generics and OTC products	Increasing
Regulatory landscape	Could introduce pricing pressures	Stable but vigilant

Strategic Recommendations

Investors should monitor patent litigation and exclusivity periods closely. Opportunities exist for market expansion through licensing agreements and formulation innovations. Strategic entry points include pre-patent expiry or during market share stabilization phases.

Key Takeaways

• DUAC is a proven, effective topical acne medication with consistent sales in the U.S.
• The upcoming patent expiry post-2024 threatens revenue stability.
• The growing global acne market offers expansion opportunities.
• Market competition from generics and OTC products increases pressure on pricing.
• Investment returns depend heavily on patent management, market expansion, and regulatory developments.

FAQs

1. When does DUAC's patent expiry occur?
Post-2024, with potential for early generic challenges.

2. How does DUAC compare to OTC benzoyl peroxide products?
It offers prescription-strength formulation with proven efficacy, but priced higher and faces competition from OTC options.

3. What are the main regulatory hurdles?
Approval for new formulations, labeling restrictions, and patent litigation outcomes.

4. Which markets are most promising for expansion?
Asia-Pacific and Latin America show growing markets for acne treatments.

5. How sensitive is DUAC's revenue to patent expiry?
Highly sensitive; revenue decline projected following patent expiration unless offset by pipeline or market expansion.

References

[1] Statista. (2023). Global acne medication market forecast.
[2] U.S. Patent Office. (2022). Patent expiry and litigation filings.
[3] MarketWatch. (2023). U.S. topical dermatology sales analysis.